Myeloproliferative Neoplasms clinical trials

Explore recruiting myeloproliferative neoplasms clinical trials.

Recruiting myeloproliferative neoplasms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myeloproliferative Neoplasms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment combination including decitabine and venetoclax. ENABLE (vENetoclax plus decitAbine treatment in Blastic phase of myeLoproliferative nEoplasms). AML2420

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia

Spain, Germany, Italy, France, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.

Norway, Germany, France, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

Long-term study evaluating the effect of givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome

Germany, Italy, Spain, Belgium, Bulgaria, France +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Myeloproliferative Neoplasms trials by city

Myeloproliferative Neoplasms in Toronto Myeloproliferative Neoplasms in Vancouver Myeloproliferative Neoplasms in Montreal Myeloproliferative Neoplasms in Calgary Myeloproliferative Neoplasms in Edmonton Myeloproliferative Neoplasms in Ottawa Myeloproliferative Neoplasms in Winnipeg Myeloproliferative Neoplasms in Quebec City Myeloproliferative Neoplasms in Hamilton Myeloproliferative Neoplasms in Kitchener Myeloproliferative Neoplasms in London Myeloproliferative Neoplasms in Halifax Myeloproliferative Neoplasms in New York Myeloproliferative Neoplasms in Los Angeles Myeloproliferative Neoplasms in Chicago Myeloproliferative Neoplasms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease